News | May 06, 2014

Devicor Medical Completes Acquisition of the HydroMARK Breast Biopsy Marker Portfolio

May 6, 2014 — Devicor Medical Products Inc. acquired the HydroMARK breast biopsy marker portfolio and related assets from Biopsy Sciences LLC.

HydroMARK was developed by John Fisher, M.D., an interventional radiologist with extensive experience in breast imaging and breast biopsy. Fisher and his team developed HydroMARK to provide physicians with a long-term ultrasound visible breast biopsy-marking alternative. Long-term ultrasound visibility provides physicians with the option to eliminate a procedural step that can reduce the anxiety and pain of traditional breast cancer treatment.

The acquisition of HydroMARK is the latest in a series of product additions by Devicor, including the addition of the Mammotome MammoTest stereotactic table, and a new distribution agreement with Faxitron on their CoreVision, core specimen radiography system. These complement recent internally developed products, Mammotome revolve and Mammotome elite. HydroMARK is currently available in most of North and South America, Europe and parts of Asia.

For more information:,,

Related Content

breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...